IMAGene

Epigenomic and machine learning models to predict pancreatic cancer


IMAGene is a European Project funded under the framework of the ERA-PerMed call “Multidisciplinary research projects on personalised medicine – development of clinical support tools for personalised medicine implementation”. The consortium gathers 20 partners located in Europe with different expertise and the common aim to develop, implement and test a comprehensive Cancer Risk prediction Algorithm to predict Pancreatic Cancer in high-risk asymptomatic subjects. Nowadays pancreatic cancer has the lowest survival rate of all cancers in Europe, with no early detection strategies available.

Era PerMed project funded in the 2021 Joint Transnational Call for Proposals (JTC 2021) co-funded by the European Commission/DG Research and Innovation


Pancreatic cancer (PC) has the lowest survival rate of all cancers in Europe, with no early detection strategies available. The IMAGene project will develop, implement and test a comprehensive Cancer Risk prediction Algorithm (CRPA) to predict PC in high-risk (HR) asymptomatic subjects.

Project Aims




Work Packages


WP1

High-risk individuals selection and development of PC risk prediction algorithm (CRPA)

WP2

Efficacy of epigenetic analysis for risk profiling and cancer screening.

WP3

Radiological screening & epigenetic analysis for early detection of cancer: feasibility

WP4

HR individuals' preferences, psycho-cognitive profiles and decisions.

WP5

Address the ethical, legal and social issues (ELSI).

WP6

Costs and utility analysis, and requisites for designing larger-scale studies.


Progress

Modeling
0%
Epigenetics
0%
Feasibility
0%
Psychology
0%
ELSI
0%
Health Economics
0%

Research team


Serena Oliveri European Institute of Oncology (Milan, Italy)
Serena Oliveri
Victor Moreno Catalan Institute of Oncology / IDIBELL (Barcelona, Spain)
Victor Moreno
Tomasz Wojdacz Pomeranian Medical University (Szczecin, Poland)
Tomasz Wojdacz
Louis Buscail Centre Hospitalier Universitaire de Toulouse (Toulouse, France)
Louis Buscail
Ovidiu Balacescu The Oncology Institute 'Prof Dr. Ion Chiricuta' (Cluj-Napoca, Romania)
Ovidiu Balacescu
Tudor Ciuleanu The Oncology Institute 'Prof Dr. Ion Chiricuta' (Cluj-Napoca, Romania)
Tudor Ciuleanu
Andrada Seicean The Oncology Institute 'Prof Dr. Ion Chiricuta' (Cluj-Napoca, Romania)
Andrada Seicean
Calin Cainap The Oncology Institute 'Prof Dr. Ion Chiricuta' (Cluj-Napoca, Romania)
Calin Cainap
Andrei Roman The Oncology Institute 'Prof Dr. Ion Chiricuta' (Cluj-Napoca, Romania)
Andrei Roman
Adrian Trifa The Oncology Institute 'Prof Dr. Ion Chiricuta' (Cluj-Napoca, Romania)
Adrian Trifa
Loredana Balacescu The Oncology Institute 'Prof Dr. Ion Chiricuta' (Cluj-Napoca, Romania)
Loredana Balacescu
Pierre Cordelier Centre Hospitalier Universitaire de Toulouse (Toulouse, France)
Pierre Cordelier
Bonanni Bernardo European Institute of Oncology (Milan, Italy)
Bonanni Bernardo
Ilaria Cutica European Institute of Oncology (Milan, Italy)
Ilaria Cutica
Gervaso Lorenzo European Institute of Oncology (Milan, Italy)
Gervaso Lorenzo
Giulia Ongaro European Institute of Oncology (Milan, Italy)
Giulia Ongaro
Clizia Cincidda European Institute of Oncology (Milan, Italy)
Clizia Cincidda
Cella Chiara Alessandra European Institute of Oncology (Milan, Italy)
Cella Chiara Alessandra
Olga Taryma-Leśniak Pomeranian Medical University (Szczecin, Poland)
Olga Taryma-Leśniak
Mireia Obón Catalan Institute of Oncology / IDIBELL (Barcelona, Spain)
Mireia Obón
Lois Riobo Catalan Institute of Oncology / IDIBELL (Barcelona, Spain)
Lois Riobo
Anna Diez-Villanueva Catalan Institute of Oncology / IDIBELL (Barcelona, Spain)
Anna Diez-Villanueva

Institutions



IEO European Institute of Oncology
PMU Pomeranian Medical University
CHUT Centre Hospitalier Universitaire de Toulouse
IOCN The Oncology Institute „Prof. Dr. Ion Chiricuţă”
IDIBELL Bellvitge Biomedical Research Institute
ICO Catalan Institute of Oncology

Funding


Era PerMEd Research Project
This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 779282.

National agencies that funded the project:


Fondazione Regionale per la Ricerca Biomedica (FRRB), Regione Lombardia, Italy

National Centre for Research and Development (NCBR), Poland


The French National Research Agency (ANR), France


Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania

Instituto de Salud Carlos III (ISCIII), co-funded by FEDER funds –a way to build Europe–, Spain

Scientific Foundation of the Spanish Association Against Cancer (FCAECC), Spain